Sciformix Announces Expansion into Europe with New Office in UK
Sciformix Corporation has opened a new office in Manchester, UK expanding its global presence and footprint to include the European region. For more than 7 years, Sciformix has been supporting life science organizations with high quality services in the areas of safety and risk management, regulatory affairs and operations and clinical research and post-approval support. The opening of the new European office demonstrates Sciformix’s scalability and preparedness to combine optimized on-shore/off-shore models that enhance client value and experience while maximizing cost benefits.
By opening an office in the UK, Sciformix will seek to better service its existing global and European clients with near-shore presence and also build new relationships with potential clients across EMEA to further grow and diversify its client and revenue base. Sciformix’s unique combination of expert talent, LEAN processes, technology innovation and flexible operations provides an attractive option to life science organizations, small and large, who are seeking to establish strategic outsourcing partnerships.
With this expansion into Europe to complement its already established presence in the US and Asia with over 750 employees, Sciformix will be within arms reach of clients’ operations across three continents. With delivery functions operating also out of the European Union (EU), clients will experience Sciformix even more as an extension of their own operations.
For years, industry groups have lobbied the UK government to help establish and nurture a life sciences hub, similar to that in Boston, US where world-class research institutions abut promising biotech start-ups and Big Pharma. The UK is now striving to brand itself as a hotbed for biotech R&D, promising new funds for start-ups, pledging to speed up its approval process and courting some major players to deepen their roots in the country. Sciformix will be able to take advantage of this and play a key role in this growth.
Manish Soman, President & CEO, Sciformix Corporation commented: “Sciformix’s long-term strategy focuses on evolving and enhancing our service and technology offerings, broadening our global reach and growing and diversifying the client and revenue base. Building a European hub will support all of these objectives. With our clients’ growth in emerging markets, it has become increasingly important for us to truly understand the local safety and regulatory challenges our clients face and to become the partner of choice when it comes to outsourcing these activities. Sciformix is such a trusted provider.”
The new office will support all service lines, however, the initial focus will be on Consulting, Safety and Risk Management, Regulatory, and Labelling services.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance